School of Medicine
Showing 12,201-12,220 of 12,928 Results
-
Clay P. Wiske, MD
Clinical Assistant Professor, Surgery - Vascular Surgery
BioDr. Wiske is a vascular surgeon in the Vascular and Endovascular Care program at Stanford Health Care. He is also a clinical assistant professor of surgery in the Department of Surgery, Division of Vascular Surgery. Dr. Wiske manages and treats the full spectrum of vascular disease, performing both open and endovascular surgery.
His clinical interests include peripheral arterial disease, venous disease, dialysis access, and aortic and peripheral aneurysms. Additionally, he has helped develop and evaluate medical devices designed to maximize the ease of treatment and limit the invasiveness of specific interventions.
Dr. Wiske has published research on a variety of topics within vascular surgery. These include the best approaches to reduce the risk of stroke associated with carotid surgery and the impact of using multidisciplinary teams to identify and treat pulmonary embolisms. Dr. Wiske has also participated in studies assessing the pace of innovation in vascular surgery, as well as policy approaches to reducing the financial burden of health care on patients.
Dr. Wiske has published his work in numerous peer-reviewed journals, including the Journal of the American Medical Association, the Journal of Vascular Surgery, and Vascular and Endovascular Surgery. He has also been an invited guest speaker at national and international meetings, including those for the Society for Vascular Surgery, American Venous Forum, and the Vascular and Endovascular Surgery Society. -
Willemijn Witkam
Postdoctoral Scholar, Dermatology
BioI am a dedicated medical doctor from The Netherlands with a passion for research specializing in dermatology. My expertise spans epidemiology, exposome, microbiome, and genetics. During my postdoc at Stanford, I will study the associations of harmful environmental exposures (air pollutants, microplastics) on (inflammatory) dermatological diseases in the lab of Dr. Eleni Linos.
-
John Witte
Professor of Epidemiology and Population Health, of Biomedical Data Science and of Genetics
Current Research and Scholarly InterestsThe Witte lab is a computational group developing and applying novel methods to decipher the mechanisms underlying complex diseases and traits. Recent research includes evaluating polygenic risk scores for trait prediction, investigating the shared genetic basis of cancer and other traits, and genetically adjusting biomarkers (e.g., prostate specific antigen) to improve disease screening.
-
Ronald Witteles
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly Interests1) Amyloidosis -- Optimizing diagnosis/therapy and discovering new treatments
2) CardioOncology -- Understanding, treating, and preventing cancer therapy-induced cardiotoxicity
3) Sarcoidosis -- Exploring novel diagnostic modalities and determining optimal treatment, with a focus on cardiac sarcoidosis -
Temesgen 'Tem' Woldeyesus
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Tem (Temesgen) is a Clinical Assistant Professor in the Department of Medicine, Division of Primary Care and Population Health. He obtained his medical degree at UCSF and continued his residency training at UCSF in Family and Community Medicine. He was selected as Chief Resident, where he further developed as a clinical educator and administrator, prior to joining the faculty group at Stanford. His academic interests include alternative models of care, clinical informatics, and digital health equity.
Dr. Tem Woldeyesus practices full-spectrum family medicine, which includes care for the entire age spectrum. He is driven to provide evidence-based, high quality, culturally competent care.
He is a native of the Bay Area. Outside of work, he enjoys spending time with his fiancée, playing (and watching) basketball, and exploring national parks. -
Albert J. Wong, M.D.
Professor of Neurosurgery
Current Research and Scholarly InterestsOur goal is to define targets for cancer therapeutics by identifying alterations in signal transduction proteins. We first identified a naturally occurring mutant EGF receptor (EGFRvIII) and then delineated its unique signal transduction pathway. This work led to the identification of Gab1 followed by the discovery that JNK is constitutively active in tumors. We intiated using altered proteins as the target for vaccination, where an EGFRvIII based vaccine appears to be highly effective.
